Alumis Inc. (NASDAQ:ALMS)
| Market Cap | 1.13B+110.1% |
| Revenue (ttm) | 7.40M-63.1% |
| Net Income | -438.96M-92.9% |
| EPS | -3.80+15.9% |
| Shares Out | 123.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,412,576 |
| Open | 9.99 |
| Previous Close | 9.90 |
| Day's Range | 9.14 - 10.11 |
| 52-Week Range | 3.76 - 31.35 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 29.57(+222.11%) |
| Earnings Date | Nov 12, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ALMS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALMS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALMS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALMS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ALMS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALMS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALMS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $89.06M |
| VXFVanguard Extended Market ETF | $27.75M |
| IWMiShares Russell 2000 ETF | $19.67M |
| VTWOVanguard Russell 2000 ETF | $12.52M |
| IWOiShares Russell 2000 Growth ETF | $7.22M |
| IBBiShares Biotechnology ETF | $6.28M |
Estimated from each fund’s disclosed top holdings × AUM
ALMS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALMS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score